

SUBpectoral Local anaesthetic Infusion following MastEctomy - version 1 (SUBLIME)

Submission date 05/09/2012	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 10/09/2012	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 29/05/2019	Condition category Cancer	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

<http://www.cancerresearchuk.org/cancer-help/trials/a-trial-looking-extra-type-pain-control-after-surgery-remove-your-breast-sublime>

Contact information

Type(s)

Scientific

Contact name

Ms Sarah Campbell

Contact details

Peninsula Clinical Trials Unit
Room N16
ITTC Building 1
Plymouth Science Park
Davy Road
Plymouth
United Kingdom
PL6 8BX
+44 (0)1752 430 392
sarah.campbell@plymouth.ac.uk

Additional identifiers

EudraCT/CTIS number

2011-005775-16

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

12964

Study information

Scientific Title

A randomised, double blind, placebo-controlled trial of continuous subpectoral local anaesthetic infusion for pain and shoulder function following mastectomy

Acronym

SUBLIME v1

Study objectives

The aim of the study is to establish whether the use of continuous local anaesthetic infusion in the sub-pectoral tissue plane can improve post-operative analgesia and quality of life for patients undergoing mastectomy with or without axillary surgery.

Ethics approval required

Old ethics approval format

Ethics approval(s)

First MREC, 06/06/2012, ref: 12/SW/0149

Study design

Randomised interventional trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet

Health condition(s) or problem(s) studied

Breast Cancer

Interventions

Participants will be randomised to receive 0.25% levobupivacaine or placebo (0.9% saline) by sub-pectoral infusion for 24 hours and will be followed up at 24 hours, 14 days and six months post-operatively.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Levobupivacaine

Primary outcome measure

Total morphine consumption, measured during the first 24 hours post-operatively

Secondary outcome measures

Total pain, measured using the Visual Analog Scale for Pain (VAS Pain) in the first 24 hours post-operatively

Overall study start date

15/10/2012

Completion date

14/08/2016

Eligibility**Key inclusion criteria**

1. All women presenting for unilateral mastectomy surgery at the Royal Cornwall Hospitals NHS Trust and Royal Devon and Exeter NHS Foundation Trust
2. Female
3. Aged 18 years and over
4. Scheduled for unilateral mastectomy with or without axillary involvement

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Female

Target number of participants

UK Sample Size: 160

Key exclusion criteria

1. Inability to give informed consent
2. Primary reconstructive surgery
3. Hypotension, hypovolaemia or any form of shock

4. Known allergy or sensitivity to local anaesthetic agents, morphine, paracetamol or ondansetron
5. Pregnancy
6. Daily opioid analgesic use
7. Inability to understand or use a PCA device
8. Inability to understand or complete the visual analogue assessment tools
9. Concurrent participation in another interventional study that might conflict with this trial

Date of first enrolment

06/12/2012

Date of final enrolment

28/07/2015

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

Royal Cornwall Hospitals NHS Trust

Truro

United Kingdom

TR1 3LJ

Study participating centre

York Teaching Hospital NHS Foundation Trust

York

United Kingdom

YO31 8HE

Sponsor information

Organisation

Royal Cornwall Hospitals NHS Trust (UK)

Sponsor details

Treliske

Truro

England
United Kingdom
TR1 3LJ

Sponsor type

Hospital/treatment centre

Website

<http://www.rcht.nhs.uk/>

ROR

<https://ror.org/026xdcm93>

Funder(s)

Funder type

Government

Funder Name

National Institute for Health Research (ref: PB-PG-0610-22342)

Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Publication and dissemination plan

To be confirmed at a later date

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol article	protocol	30/09/2014		Yes	No
HRA research summary			28/06/2023	No	No